###### Strengths and limitations of this study

This trial is a well-designed pilot study to achieve biochemically and clinically relevant outcomes.Significant preliminary research has been performed in order to appropriately design the study to fill gaps in current knowledge.This is the first randomised, placebo-controlled, dose-finding trial of melatonin in the field of infertility worldwide and if successful, has the potential to provide a foundation for future large RCTs.A cross-over design will be used as this is known to improve recruitment rates.

Introduction {#s1}
============

Humans are aerobic organisms and when oxygen is utilised in metabolic processes, free oxygen radicals are created as a consequence. These radicals are oxidants and contain 'free' valence electrons, making them highly unstable and therefore reactive, capable of causing injury to cells. This occurs by accepting electrons from another molecule (a reductant) in order to reach stability. In doing so, the chemical structure of the reductant is changed, and may no longer be able to perform its designated function. In fact, often the reductant can then produce or sometimes even become an oxidant having the potential to cause oxidative stress in its own right.[@R1] Antioxidative agents are present endogenously and can also be administered exogenously. They are designed to reduce free radicals by donating electrons to stabilise the free radical.[@R2] The term 'reactive oxygen species' (ROS) not only includes free radicals but also molecularly stable non-radical molecules which contain oxygen and are capable of causing oxidative stress, such as hydrogen peroxide (H~2~O~2~).[@R3] While ROS are necessary for essential physiological processes, an overabundance can result in cellular and tissue damage and this is commonly referred to as 'oxidative stress'.[@R4] Oxidative stress can be measured in bodily fluids by markers including 8-hydroxy-2′-deoxyguanosine (8-OHdg).[@R5]

Over recent years, the potential role of oxidative stress in the outcomes of assisted reproductive technology (ART) has been gaining increasing attention, in particular with regard to *in vitro* fertilisation (IVF) and intracytoplasmic sperm injection (ICSI). This is perhaps not surprising given that ART exposes both oocytes and embryos to high levels of superoxide-free radicals during gamete and embryo culture.[@R6] In addition to the culture conditions, *in vitro* the oocytes are not afforded the normal protection of the antioxidant-rich follicular fluid or surrounding cumulus cells, leaving them more susceptible to oxidative damage.[@R7] [@R8] Reproductive processes such as chromosome segregation (resulting in euploid oocytes), polar body extrusion (necessary for haploid oocytes), fertilisation and early cleavage (to avoid arrested embryos) require energy. As the average age of women seeking fertility treatment rises, the level of ROS and subsequent oxidative stress increases, resulting in mitochondrial DNA mutations which in turn affect ATP production in the oocyte. Without the necessary ATP, required cellular processes cannot occur correctly, having a direct effect on the quality of the oocyte, embryo and the final outcome of the IVF procedure.[@R9] [@R10]

It has been shown that oocyte quality begins to deteriorate immediately following ovulation. This has been thought to be an inflammatory-driven oxidative stress process[@R11] whereby the production of cytokines and proteases is associated with an increase in ROS which in turn impair oocyte maturation.[@R12] Evidence of oxidative damage in *in vitro* oocytes has been shown to exist as early as 8 h after ovulation.[@R15] Nor surprisingly it has been shown that high levels of the oxidative stress in the follicular fluid of infertile women are associated with poor oocyte maturation and embryo quality, and that inducers of oxidative stress can be used to inhibit oocyte maturation.[@R5] [@R12] Together, these observations highlight the importance of oxidative stress in the developing follicle and in the future success of fertilisation, whether *in vivo* or *in vitro*.

Recently, it has been shown that melatonin, a neurohormone secreted from the pineal gland, has important oxygen-scavenging properties which naturally mitigate oxidative stress by both neutralising ROS in human tissues and by inducing endogenous antioxidant enzymes.[@R16] Melatonin has been shown to be beneficial as an adjuvant therapy in the management of many medical conditions in which oxidative stress has been implicated, including diabetes, glaucoma, irritable bowel syndrome and fertility.[@R19]

The effects of melatonin supplementation on culture media,[@R12] [@R21] [@R23] gametes,[@R5] [@R15] [@R28] embryos[@R15] [@R29] [@R30] and luteal function[@R31] have been identified as useful areas for investigation. Human clinical studies have begun recently, with emphasis on oral supplementation of melatonin during the stimulation cycle and its effects on oocyte and embryo quality.[@R12] [@R36]

Importantly, melatonin has a remarkably benign safety profile in animal and human studies. A mouse study investigating dose-related effects of melatonin on ovarian grafts found that doses at 200 mg/kg/day have immunosuppressant effects, leading to prolongation of graft survival, however, also resulted in a reduction in healthy follicles. They concluded that doses of greater than 20 mg/kg/day resulted in a reduction in healthy follicles and ovarian size.[@R40] The maternal lowest observed adverse effect level, the lowest level at which an adverse event was observed, appears to be around 200 mg/kg/day, equivalent to over 1 g/day for humans. Furthermore, in rodent studies, no significant adverse effects on either the embryo or fetus have been reported for up to doses of 200 mg/kg/day.[@R41] There have been several randomised controlled trials (RCTs) addressing high doses of melatonin in human adults and children,[@R42] and reports have established that toxicity levels in humans are not reached until a daily dose of at least 5 mg/kg.[@R47]

Rationale {#s2}
=========

In the USA, in 2011, only 1 in 4 of all IVF cycles resulted in clinical pregnancy with less than 1 in 5 cycles resulting in live birth.[@R48] That is, 4 out of 5 IVF cycles do not result in a live baby. Clearly there is much room for further improvement, if only to meet societal expectations and reduce healthcare costs. Continued research into novel adjuvant therapies designed to improve IVF outcomes is therefore merited. Several human and animal studies support the use of melatonin in the treatment of infertility, with beneficial actions being largely attributed to its antioxidant properties. Furthermore, melatonin receptors are found on granulosa cells, oocytes and embryos,[@R49] with intrafollicular melatonin concentrations being significantly higher than those found in serum, again suggesting a physiological role in reproduction.[@R39] [@R50] [@R51] The human studies addressing the use of melatonin in infertility treatment undertaken to date have been small and not placebo-controlled. None have attempted to identify an optimal dose.[@R36] [@R52] Furthermore, interpretation of any outcomes has been hampered by the within-patient comparison design, where patients act as their own controls.[@R12] [@R39] [@R53]

We have designed this study to be the first randomised, placebo-controlled, dose-finding clinical trial to investigate the effect(s), if any, of oral melatonin on the clinical pregnancy rate following IVF/ICSI treatment.

Aims {#s3}
====

The overall aim of this trial is to determine whether oral melatonin administration can improve the outcomes of IVF/ICSI. In order to address this, we will determine whether melatonin administration has a dose--response effect in women undergoing IVF/ICSI on: Biochemical markers of follicle and oocyte health (melatonin, 8-OHdg, progesterone, oestradiol);Sonographic markers of follicle health;Patient sleepiness;Pregnancy rate following IVF/ICSI.

Methods and analyses {#s4}
====================

This protocol has been designed in accordance with the SPIRIT 2013 Guidelines.[@R54] Recruitment will start in July 2014. This will occur over 2 years. Analysis and dissemination will occur after this period of time. The study is expected to be completed by February 2017.

Study design {#s5}
============

Pilot phase II cross-over double-blinded randomised placebo-controlled dose--response trial.

Participants {#s6}
============

We plan to recruit a total of 160 infertile women undergoing IVF/ICSI.

Study setting {#s7}
=============

Patients will be recruited from Monash IVF infertility clinics in Melbourne, Australia over a period of 2 years.

Interventions to be measured {#s8}
============================

This trial will have four arms. All capsules will be indistinguishable from each other. Placebo capsule taken twice per day;2 mg melatonin capsule twice per day (4 mg/day total);4 mg melatonin capsule twice per day (8 mg/day total);8 mg melatonin capsule twice per day (16 mg/day total).

Primary outcome {#s9}
===============

Clinical pregnancy rate,[@R55] defined as the presence of a live pregnancy in the uterine cavity at a transvaginal ultrasound at 6--8 weeks' gestation.

Secondary outcomes {#s10}
==================

See [table 1](#BMJOPEN2014005986TB1){ref-type="table"} for details.

###### 

Clinical secondary outcomes

  Clinical outcomes                                 Definition
  ------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Live birth rate                                   Birth of a live baby after 24 weeks gestation
  Miscarriage rate                                  Loss of a diagnosed clinical pregnancy before 20 weeks gestation
  Sleepiness score                                  Based on Karolinska[@R56] sleepiness scale during trial medication administration
  Pregnancy complication and adverse events rates   Including OHSS, multiple pregnancy, congenital or chromosomal abnormalities, stillbirth, pre-eclampsia, delivery before 34 weeks, delivery between 34 and 37 weeks, placenta praevia, gestational diabetes, low birth weight
  Embryological outcomes                            
  Total number of oocytes collected                 
  Oocyte maturity                                   
  Total number of embryos                           
  Embryo quality                                    
  Fertilisation rate                                The proportion of oocytes that become fertilised
  Utilisation rate                                  Proportion of zygotes undergoing embryo transfer or cryopreservation to oocytes fertilised
  Biochemical outcomes                              
  Biochemical pregnancy rate                        Presence of serum hCG level of \>25 IU/L on day 16 after embryo transfer
  Melatonin levels in serum                         At baseline and prior to oocyte collection
  Melatonin levels in follicular fluid              Taken from leading follicle from each ovary at time of oocyte collection
  8-OHdg levels in serum                            At baseline and prior to oocyte collection
  8-OHdg levels in follicular fluid                 Taken from leading follicle from each ovary at time of oocyte collection
  Oestradiol and progesterone levels in serum       Taken at baseline, during treatment and at the time of oocyte collection
                                                    
  Sonographic outcomes                              
  Follicular blood flow                             Measured on last transvaginal ultrasound with power Doppler prior to oocyte collection
  Uterine artery blood flow                         Measured on last transvaginal ultrasound with power Doppler prior to oocyte collection

hCG, human chorionic gonadotropin; OHSS, ovarian hyperstimulation syndrome; 8-OHdg, 8-hydroxy-2′-deoxyguanosine.

Sample size {#s11}
===========

As this is a pilot dose-finding study, without precedence on which to base accurate power calculations, a power calculation has not been performed. Part of our aim is to provide clarification allowing for larger randomised trials to be designed in the future. We hypothesise that melatonin will have a positive dose--response effect on clinical pregnancy rates after IVF/ICSI. We have chosen a convenience sample of 160 participants, 40 in each of the four groups, in order to assess plausible morphological, biochemical and sonographic surrogate markers for oocyte quality, as well as to provide an indication of the effect size for each dose for our primary outcome, clinical pregnancy rate. Conservatively estimating that, in total, 50% of patients (n=80) do not get pregnant after their first cycle, we may assume that 60 patients will participate in the cross-over arm (allowing for drop-outs) in their second cycle and be allocated to a different treatment group.

Inclusion criteria {#s12}
==================

1.  Undergoing first cycle of IVF or ICSI;

2.  Age between 18 and 45;

3.  Body mass index between 18 and 35;

4.  Undergoing a gonadotrophin releasing hormone (GnRH) antagonist cycle (without oral contraceptive pill (OCP) scheduling).

Exclusion criteria {#s13}
==================

1.  Current untreated pelvic pathology---moderate-to-severe endometriosis, submucosal uterine fibroids/polyps assessed by the treating specialist to affect fertility, pelvic inflammatory disease, uterine malformations, Asherman's syndrome and hydrosalpinx.

2.  Currently enrolled in another interventional clinical trial.

3.  Concurrent use of other adjuvant therapies (e.g. Chinese herbs, acupuncture).

4.  Current pregnancy.

5.  Malignancy or other contraindication to IVF.

6.  Autoimmune disorders.

7.  Undergoing preimplantation genetic diagnosis.

8.  Hypersensitivity to melatonin or its metabolites.

9.  Concurrent use of any of the following medications: Fluvoxamine (e.g. luvox, movox, voxam);Cimetidine (e.g. magicul, tagamet);Quinolones and other CYP1A2 inhibitors (ciprofloxacin, avalox);Carbamazepine (e.g. tegretol), rifampicin (e.g. rifadin) and other CYP1A2 inducers;Zolpidem (e.g. stilnox), zopiclone (e.g. imovane) and other non-benzodiazepine hypnotics.

10. Inability to comply with trial protocol.

Concomitant care {#s14}
================

Aside from trial protocol and inclusion/exclusion criteria listed above, standard concomitant care, such as folic acid supplements, is permitted.

Participant enrolment {#s15}
=====================

This trial will begin recruitment at the level of the infertility specialist. Once identified as requiring IVF/ICSI, and satisfying inclusion and exclusion criteria, the patient will be provided with detailed written information about the trial protocol. After approximately 1 week, the patient will be approached and written informed consent will be obtained by the principle investigator at the first visit with the infertility clinic nurse. Baseline blood tests will be taken and basic demographic information including aetiology of infertility will be recorded. The patient will then be randomised by the principle investigator (see below) to one of the study arms and provided with the trial medication. The participant will start taking the trial medication on the day that ovarian stimulation injections begin (days 2--3 of menses) at 08:00 and 22:00 each day, with the last capsule being taken at 22:00 the night before oocyte collection.

For a summarised participant timeline, see [figures 1](#BMJOPEN2014005986F1){ref-type="fig"} and [2](#BMJOPEN2014005986F2){ref-type="fig"}.

![Participant timeline schematic---first cycle. ^a^Placebo, melatonin 2 mg twice daily, melatonin 4 mg twice daily, melatonin 8 mg twice daily. Note: patients who are not pregnant after their first cycle will be offered a second cycle with a different trial medication ([figure 2](#BMJOPEN2014005986F2){ref-type="fig"}). hCG, human chorionic gonadotropin; 8-OHdg, 8-hydroxy-2′-deoxyguanosine.](bmjopen2014005986f01){#BMJOPEN2014005986F1}

![Participant timeline schematic---second cycle in those not pregnant after their first cycle. ^a^For participants who do not become pregnant in their first cycle, each will be offered allocation to the next treatment arm for their second cycle (i.e. A will be allocated to B, B to C, C to D and D to A). ET, embryo transfer; hCG, human chorionic gonadotropin.](bmjopen2014005986f02){#BMJOPEN2014005986F2}

Allocation concealment, blinding and randomisation {#s16}
==================================================

Association of particular treatment effects (e.g. sleepiness) with certain randomisation codes may become apparent during the trial, and to prevent further allocation bias, proper concealment of treatment allocation is necessary. Each treatment arm will be randomly allocated a letter (A, B, C or D) by way of opaque sealed envelope. Randomisation will be computerised and patients will be randomised at a ratio of 1:1:1:1 to one of the groups, A--D, using the minimisation method, a method of randomisation accounting for factors known to affect the outcome used in small trials to prevent selection bias.[@R57]

With a cross-over design, improved patient recruitment is very likely because all non-pregnant participants will be guaranteed at least one cycle with one of the doses of melatonin.[@R58] [@R59] After completing the first study cycle, those participants who are not pregnant will be recruited for the cross-over cycle in which they will be assigned the next treatment arm. For example, if a participant were allocated to treatment group A in their first cycle and did not become pregnant, they would be offered allocation to group B in their second cycle and so on. The half life of melatonin is short, being completely eliminated from the body shortly after 24 h.[@R60] Once patients have had their first stimulated cycle of treatment, a second stimulated cycle will routinely not start until at least 4 weeks after the negative pregnancy test (approximately 6 weeks after last melatonin dose), much longer than the elimination time for melatonin. This will be a sufficient washout period prior to inclusion in a second cycle.

Participants will be blinded by receiving identical-appearing unmarked capsules. All trial researchers will be blinded to treatment allocation group until after analyses are performed at the completion of the trial. A Data Safety Monitoring Committee (see *Adverse events and data safety and monitoring* section for details) and dispensing pharmacy will be aware of allocation to allow identification of any unbalanced or multiple serious adverse events that may necessitate emergency unblinding of researchers and participants.

Adherence and retention {#s17}
=======================

In order to ensure the integrity of study data, participant adherence to trial protocol will be assessed on a medication administration record updated daily by the participant. At oocyte collection, participants will return medication bottles and compliance will be confirmed by counting remaining tablets. This will be recorded on individual patient compliance forms and patient record forms. Every reasonable effort will be made from the time of enrolment until the end of follow-up to maintain contact with and maintain participant\'s participation in the trial.

Analysis plan {#s18}
=============

SPSS V.22.0 (IBM, Armonk, New York, USA) will be used for data analysis. Primary analysis will occur by the intention-to-treat principle. A secondary analysis will be performed for 'actual treatment received'. We also intend to perform a separate subanalysis on the data from the first cycle only. Statistical analyses will be performed using χ^2^ tests for dichotomous categorical outcome variables. Clinical and demographic data will be analysed with parametric tests if they are normally distributed (analysis of variance (ANOVA) with Bonferroni adjustment), otherwise appropriate non-parametric tests will be implemented (Kruskal-Wallis for between group analyses). Within patient changes (paired data), e.g. when comparing serum levels of melatonin at baseline and after treatment, will be compared using repeated measures ANOVA or Wilcoxon signed-rank test depending on normality of data. A p\<0.05 will be considered statistically significant. Where statistically sound, adjusted ORs will be calculated to account for confounders or effect modifiers. To account for missing data, two analyses will be run, with the first excluding missing values and the second by imputation of missing values to determine how conclusions are affected. The SPSS multiple imputation routine (MCMC algorithm known as Fully Conditional Specification) will be used to handle missing data.

Adverse events and data safety and monitoring {#s19}
=============================================

An independent Data Safety and Monitoring Committee (DSMC) has been established at Monash Health in order to monitor occurrences of adverse events. The principle investigator will be available by telephone at all times during the trial and participants will be provided with contact details in case of any adverse events. Participants will also be interviewed at the time of their ultrasound and the day of oocyte collection to ascertain the occurrence of any adverse events. Serious adverse events will be recorded separately and followed up until resolution. Such events will be reported to the Monash Health, Monash University, Monash Surgical Private Hospital and Epworth HealthCare Human Research Ethics Committees, the Monash Health DSMC, the Monash Health Therapeutics Committee and, if directed by HREC, to the Australian Therapeutics and Goods Administration.

Trial modification and discontinuation {#s20}
======================================

In the absence of adverse events, the medication regimen will not be modified once started. If other protocol changes are deemed necessary by the investigating team, ethics approval will be sought from all approving Human Research Ethics Committees. Once approved, protocol amendments will be notified to all investigators, administrators (e.g. dispensing pharmacy) and trial participants via telephone.

Patients are permitted to discontinue their inclusion in the trial at any point in time at their request or following an unexpected serious adverse event as described above. The DSMC will perform an interim analysis specifically assessing adverse events after 50% of participants have been recruited. Otherwise, the trial will cease follow-up once patients have given birth from a trial treatment cycle.

Data collection, informed consent forms and confidentiality {#s21}
===========================================================

Data will be recorded in hardcopy and electronic form. Hardcopies will be stored in a secured filing cabinet at the administering institution. Electronic copies will be stored in encrypted files on a password protected computer. All data will be kept for 15 years; following this time, hardcopies will be destroyed by shredding or burning and electronic copies will be deleted by formatting. Organic samples will be stored until analysis in a secured locked temperature-controlled freezer at the Monash Institute of Medical Research that can only be accessed by authorised staff. Samples and participant records will not contain any directly identifiable information. No additional biological samples will be kept for use in ancillary studies.

For access to data collection forms, including sleep diaries, medication compliance and informed consent forms, please contact the principle investigator.

Ethics and dissemination {#s22}
========================

Data analysis, interpretation and conclusions will be presented at national and international conferences and published in peer-reviewed journals. De-identified summary results will also be made publically available on the Monash IVF website.

Discussion {#s23}
==========

The Melatonin in ART (MIART) trial has the potential to improve IVF treatment protocols, with both immediate and translational benefit to patients. If melatonin is found to improve outcomes after IVF/ICSI, it may become a routine part of management of the infertile couple. We aim to set precedence and a framework by which others may structure further investigation into melatonin and other adjuvant therapies in the future. The intention of this study is as a pilot trial, primarily designed to provide unbiased data as a foundation for further research into this area. It is anticipated that the effect size observed in this trial will be useful to more appropriately power subsequent RCTs with the most effective dose of melatonin. In summary, MIART will be the first trial designed to determine a dose--response relationship of melatonin on biochemical and physiological markers of follicle health and also clinical pregnancy rates.
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